Evidence map›Paper›PMID 35174321›Full record

ArticleImmuno-oncology technology2021

Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the

V H Koelzer, P Herzig, I Zlobec, V Heinzelmann, D Lardinois, E Walseng, C Rader, K D Mertz, A Zippelius, D S Thommen

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immuno-oncology technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

V H KoelzerDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Switzerland.
P HerzigDepartment of Biomedicine, University Hospital Basel, University of Basel, Switzerland.
I ZlobecInstitute of Pathology, University of Bern, Switzerland.
V HeinzelmannDepartment of Gynaecology and Obstetrics, University Hospital Basel, Switzerland.
D LardinoisDepartment of Surgery, University Hospital Basel, Switzerland.
E WalsengDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, USA.
C RaderDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, USA.
K D MertzInstitute of Pathology, Cantonal Hospital Baselland, Switzerland.
A ZippeliusDepartment of Biomedicine, University Hospital Basel, University of Basel, Switzerland.
D S ThommenDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
University Hospital of Basel · CHScripps Research Institute · USThe Netherlands Cancer Institute · NLUniversity Hospital of Zurich · CHUniversity of Basel · CHUniversity of Bern · CH

Funding

Chemically Programmed Bispecific Antibodies for Cancer TherapyR01CA181258 · NCI · SCRIPPS FLORIDA · PI RADER, CHRISTOPH · 2014 to 2018
$2.0M
NCI NIH HHS R01 CA181258
6 · The paper itself

Abstract

backgroundCancer immunotherapy elicits functional activation and changes in immune cell distribution in cancer. Tumour heterogeneity is a reason for treatment failure but is difficult to capture in experimental settings. This proof-of-principle study describes the integrated functional and digital spatial profiling platform MATERIALS AND

methods

resultsEx-vivo DART stimulation induces upregulation of multiple activation markers in CD4+ and CD8+ T-cell populations and secretion of pro-inflammatory cytokines in FOLR1-positive tumour specimens. This response was reduced or absent in tissue samples that did not express FOLR1. Immunological responses were driven by a strong induction of interferon gamma (IFNγ) and IFNγ-induced chemokines suggestive of activation of cytotoxic or Th1-like T cells. Ex-vivo DART treatment led to a numerical increase in effector T cells and an upregulation of immune activation markers in the tumour microenvironment as captured by digital image analysis. Analysis of immune activation in tumour and stromal regions further supported the potential of the platform to measure local differences in cell-type-specific activation patterns.

conclusions

Indexed as

computer-assisted image processingdigital pathologyEx-vivo modelsimmunotherapytumour biomarkerstumour microenvironment

Identifiers

PMID35174321
PMCPMC8846576
OpenAlexW3176750674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.